Search

Your search keyword '"Linkesch, W."' showing total 594 results
Start Over Author "Linkesch, W."
594 results on '"Linkesch, W."'

2. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Tucunduva, L, Ruggeri, A, Sanz, G, Furst, S, Socié, G, Michallet, M, Arcese, W, Milpied, N, Yakoub-Agha, I, Linkesch, W, Cornelissen, J, Mannone, L, Iori, A P, Ribera, J-M, Sanz, J, Montesinos, P, Purtill, D, Labopin, M, Gluckman, E, Mohty, M, and Rocha, V

Published
2014
Full Text
View/download PDF

5. Recombinant Human Erythropoietin After Bone Marrow Transplantation — A Placebo Controlled Trial

Author

Link, H., Boogaerts, M. A., Fauser, A., Or, R., Reiffers, J., Gorin, N. C., Carella, A., Mandelli, F., Burdach, S., Ferrant, A., Linkesch, W., Tura, S., Bacigalupo, A., Schindel, F., Heinrichs, H., Hiddemann, W., editor, Plunkett, W., editor, Büchner, T., editor, Ritter, J., editor, Wörmann, B., editor, Keating, M. J., editor, and Creutzig, U., editor

Published
1996
Full Text
View/download PDF

7. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Author

Gattermann N., Finelli C., Della Porta M., Fenaux P., Ganser A., Guerci-Bresler A., Schmid M., Taylor K., Vassilieff D., Habr D., Domokos G., Roubert B., Rose C., Agaoglu L., Alimena G., Alonso D., Ame S., Angelucci E., Arrizabalaga B., Athanasiou-Metaxa M., Augustson B., Aydinok Y., Baba A., Baccarani M., Beck J., Beris P., Beyne-Rauzy O., Birgens H., Bordessoule D., Borgna-Pignatti C., Bosly A., Bouabdallah K., Bowden D., Bowen D., Bron D., Cappellini M.D., Capra M., Cartron G., Cazzola M., Chalkias C., Chan L.L., Chancharunee S., Chapman C., Charoenkwan P., Chasapopoulou E., Cheze S., Chuansumrit A., Cianciulli P., Dauriac C., Delforge M., Dolken G., Dombret H., Duyster J., Economopoulos T., Ehninger G., Elalfy M., El-Beshlawy A., Enggaard L., Fillet G., Filosa A., Forni G., Galanello R., Gastl G., Giraudier S., Goldfarb A., Grigg A., Gumruk F., Ha S.Y., Haase D., Heinrich B., Hertzberg M., Ho J., Hsu H.-C., Huang S., Hunault-Berger M., Inusa B., Jaulmes D., Jensen J., Kattamis A., Kilinc Y., Kim K.-H., Kinsey S., Kjeldsen L., Koren A., Lai M.E., Lai Y., Lee J.-W., Lee K.-H., Lee S.-H., Legros L., Li C., Li C.-K., Li Q., Lin K.-H., Linkesch W., Lubbert M., Lutz D., Mohamed Thalha A.J., Mufti G., Muus P., Nobile F., Papadopoulos N., Perrotta S., Petrini M., Pfeilstocker M., Piga A., Poole J., Porter J.B., Pungolino E., Quarta G., Ravoet C., Jolimont Lobbes H.H., Remacha A.F., Roy L., Saglio G., Sanz G., Schmugge M., Schots H., Secchi G., Seymour J.F., Shah F., Shah H., Shen Z., Slama B., Sutcharitchan P., Taher A., Tamary H., Tesch H.-J., Thein S.L., Troncy J., Villegas A., Viprakasit V., Wainwright L., Wassmann B., Wettervald M., Will A., Wormann B., Wright J., Yeh S.-P., Yoon S.-S., Zoumbos N.C., Zweegman S., Gattermann N., Finelli C., Della Porta M., Fenaux P., Ganser A., Guerci-Bresler A., Schmid M., Taylor K., Vassilieff D., Habr D., Domokos G., Roubert B., Rose C., Agaoglu L., Alimena G., Alonso D., Ame S., Angelucci E., Arrizabalaga B., Athanasiou-Metaxa M., Augustson B., Aydinok Y., Baba A., Baccarani M., Beck J., Beris P., Beyne-Rauzy O., Birgens H., Bordessoule D., Borgna-Pignatti C., Bosly A., Bouabdallah K., Bowden D., Bowen D., Bron D., Cappellini M.D., Capra M., Cartron G., Cazzola M., Chalkias C., Chan L.L., Chancharunee S., Chapman C., Charoenkwan P., Chasapopoulou E., Cheze S., Chuansumrit A., Cianciulli P., Dauriac C., Delforge M., Dolken G., Dombret H., Duyster J., Economopoulos T., Ehninger G., Elalfy M., El-Beshlawy A., Enggaard L., Fillet G., Filosa A., Forni G., Galanello R., Gastl G., Giraudier S., Goldfarb A., Grigg A., Gumruk F., Ha S.Y., Haase D., Heinrich B., Hertzberg M., Ho J., Hsu H.-C., Huang S., Hunault-Berger M., Inusa B., Jaulmes D., Jensen J., Kattamis A., Kilinc Y., Kim K.-H., Kinsey S., Kjeldsen L., Koren A., Lai M.E., Lai Y., Lee J.-W., Lee K.-H., Lee S.-H., Legros L., Li C., Li C.-K., Li Q., Lin K.-H., Linkesch W., Lubbert M., Lutz D., Mohamed Thalha A.J., Mufti G., Muus P., Nobile F., Papadopoulos N., Perrotta S., Petrini M., Pfeilstocker M., Piga A., Poole J., Porter J.B., Pungolino E., Quarta G., Ravoet C., Jolimont Lobbes H.H., Remacha A.F., Roy L., Saglio G., Sanz G., Schmugge M., Schots H., Secchi G., Seymour J.F., Shah F., Shah H., Shen Z., Slama B., Sutcharitchan P., Taher A., Tamary H., Tesch H.-J., Thein S.L., Troncy J., Villegas A., Viprakasit V., Wainwright L., Wassmann B., Wettervald M., Will A., Wormann B., Wright J., Yeh S.-P., Yoon S.-S., Zoumbos N.C., and Zweegman S.

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ~50% were chelation-naive. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naive or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS. © 2010 Elsevier Ltd.

Published
2021

11. UNRELATED CORD BLOOD TRANSPLANTATION IN ADULTS WITH PRIMARY AND SECONDARY MYELOFIBROSIS: A RETROSPECTIVE STUDY ON BEHALF OF EUROCORD AND CMWP-EBMT: PH-O107

Author

Giannotti, F., Ruggeri, A., Deconinck, E., Mohty, M., Michallet, M., Sanz, G., Chevallier, P., Cahn, J.-Y., Legrand, F., Rovira, M., Passweg, J., Cornelissen, J. J., Sierra, J., Nguyen, S., Maillard, N., Yakoub-Agha, I., Linkesch, W., Cannell, P., Marcatti, M., Bay, J.-O., Rocha, V., Kröger, N., Gluckman, E., Olavarria, E., and Robin, M.

Published
2014

38. Early allogeneic stem cell transplantation for peripheral T-cell lymphoma results in a lower relapse rate and a higher non-relapse mortality than high-dose therapy followed by autologous transplantation. Results of a retrospective EBMT analysis: O258

Author

Nickelsen, M., Canals, C., Kyriakou, C., Schmitz, N., Engelhardt, M., Relander, T., Linkesch, W., Koza, V., Meloni, G., Caballero, D., Lopez-Guillermo, A., Indrac, K., Wandt, H., Theorin, N., Glass, B., Buzyn, A., Wulf, G., Conde, E., Socie, G., and Sureda, A.

Published
2009

39. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT: 221

Author

Garderet, L., Iacobelli, S., Moreau, P., Onida, F., Koenecke, C., Pabst, T., Doyen, C., Crawley, C., Hajek, R., Linkesch, W., Harousseau, J. L., Michallet, M., Doran, Z., de Witte, T., Niederwieser, D., Gahrton, G., and Morris, C.

Published
2009

43. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone to treat multiple myeloma patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT

Author

Garderet, L., Iacobelli, S., Moreau, P., Onida, F., Könecke, C., Pabst, T., Doyen, C., Crawley, C., Hajek, R., Linkesch, W., Harousseau, J.-L., Michallet, M., Doran, Z., de Witte, T., Niederwieser, D., Gahrton, G., and Morris, C.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results